Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote
An FDA advisory committee is voting on whether to approve the first multi-cancer blood test, which claims to detect 50 types of cancer. Approval could lead to Medicare coverage and set a precedent for future diagnostic screening technologies.
Why it matters
This decision could fundamentally change cancer screening protocols and the financial landscape for diagnostic medical companies.
OlekStock/Getty Images A key advisory committee that reviews medical devices for the Food and Drug Administration will meet today to vote on whether the agency should approve the first multi-cancer blood test. Grail, the company that makes the Galleri blood test under review, says it can detect up to 50 forms of cancer, many of which are not routinely screened for today.
Living Better To catch colorectal cancer early, advocates push to make 'poop talk' OK The panel of independent experts will hear from Grail, FDA officials and the public before voting on a recommendation. The FDA often follows the advice from its panels, but does not have to. Ultimate approval by the agency could mean insurance reimbursement for the test, which costs $949.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in